CARTISTEM® Achieves Significant Efficacy Milestones in Japan's Phase 3 Clinical Trials
MEDIPOST has announced the successful completion of its Phase 3 clinical trials for CARTISTEM®, a groundbreaking treatment for knee osteoarthritis, conducted in Japan. The results revealed that CARTISTEM® surpassed all primary and secondary efficacy endpoints, suggesting significant advancements in both pain relief and functional improvements for patients, in addition to promoting cartilage regeneration.
Conducted across 13 hospital sites, the trial enrolled 130 participants, with 59 receiving CARTISTEM® and 61 receiving a hyaluronic acid (HA) control. The study utilized a randomized, controlled design, ensuring the demographics and clinical characteristics among participants were balanced, which enhances the reliability of the findings. Both groups presented similar baseline parameters, proving the study's integrity.
CARTISTEM® showed statistically significant improvements over the control group in key metrics such as the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the International Cartilage Repair Society (ICRS) Grade. The results indicated a p-value of less than 0.0001 for WOMAC, confirming its efficacy in enhancing knee pain and function. Additionally, the Visual Analog Scale (VAS) scores for pain intensity and other assessments like the International Knee Documentation Committee (IKDC) and Knee Injury and Osteoarthritis Outcome Score (KOOS), all demonstrated remarkable improvements.
Remarkably, these improvements were consistent throughout secondary endpoints, reaffirming the efficacy of CARTISTEM®. The results indicated an exemplary safety profile, with all serious adverse events being determined not to have a causal link with the treatment. Notably, the results from the Japanese trials align with those from ongoing U.S. Phase 3 trials, boosting confidence in CARTISTEM®'s potential.
Antonio Lee, the Global President of MEDIPOST, expressed optimism, stating that the results not only validate CARTISTEM®’s strong efficacy but also emphasize its capability for cartilage regeneration. The consistency of positive outcomes across various measures strengthens the treatment's prospects as a Disease-Modifying OA Drug (DMOAD).
Looking ahead, MEDIPOST is poised to fast-track its entry into the Japanese market with plans to submit a biologics license application by the end of 2026. This ambitious goal is backed by an exclusive partnership with Teikoku Seiyaku Co., Ltd., ensuring a streamlined path to market.
The anticipated marketing authorization application is a critical step, expected to drive MEDIPOST's business outcomes in Japan. If approved, the company expects to generate substantial revenue from product sales and milestone payments, marking a new era in osteoarthritis treatment options.
In summary, the achievement of CARTISTEM® in the Phase 3 trials in Japan not only cements its clinical efficacy and safety but also signifies an essential step for MEDIPOST’s global ambitions. The promising results encourage stakeholders and investors, heralding a new chapter in the treatment landscape for knee osteoarthritis. The future looks bright for CARTISTEM® as it becomes a pivotal player in addressing the needs of patients suffering from osteoarthritis pain and mobility issues, enhancing their overall quality of life.
Conducted across 13 hospital sites, the trial enrolled 130 participants, with 59 receiving CARTISTEM® and 61 receiving a hyaluronic acid (HA) control. The study utilized a randomized, controlled design, ensuring the demographics and clinical characteristics among participants were balanced, which enhances the reliability of the findings. Both groups presented similar baseline parameters, proving the study's integrity.
CARTISTEM® showed statistically significant improvements over the control group in key metrics such as the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the International Cartilage Repair Society (ICRS) Grade. The results indicated a p-value of less than 0.0001 for WOMAC, confirming its efficacy in enhancing knee pain and function. Additionally, the Visual Analog Scale (VAS) scores for pain intensity and other assessments like the International Knee Documentation Committee (IKDC) and Knee Injury and Osteoarthritis Outcome Score (KOOS), all demonstrated remarkable improvements.
Remarkably, these improvements were consistent throughout secondary endpoints, reaffirming the efficacy of CARTISTEM®. The results indicated an exemplary safety profile, with all serious adverse events being determined not to have a causal link with the treatment. Notably, the results from the Japanese trials align with those from ongoing U.S. Phase 3 trials, boosting confidence in CARTISTEM®'s potential.
Antonio Lee, the Global President of MEDIPOST, expressed optimism, stating that the results not only validate CARTISTEM®’s strong efficacy but also emphasize its capability for cartilage regeneration. The consistency of positive outcomes across various measures strengthens the treatment's prospects as a Disease-Modifying OA Drug (DMOAD).
Looking ahead, MEDIPOST is poised to fast-track its entry into the Japanese market with plans to submit a biologics license application by the end of 2026. This ambitious goal is backed by an exclusive partnership with Teikoku Seiyaku Co., Ltd., ensuring a streamlined path to market.
The anticipated marketing authorization application is a critical step, expected to drive MEDIPOST's business outcomes in Japan. If approved, the company expects to generate substantial revenue from product sales and milestone payments, marking a new era in osteoarthritis treatment options.
In summary, the achievement of CARTISTEM® in the Phase 3 trials in Japan not only cements its clinical efficacy and safety but also signifies an essential step for MEDIPOST’s global ambitions. The promising results encourage stakeholders and investors, heralding a new chapter in the treatment landscape for knee osteoarthritis. The future looks bright for CARTISTEM® as it becomes a pivotal player in addressing the needs of patients suffering from osteoarthritis pain and mobility issues, enhancing their overall quality of life.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.